Biotech exposure from discovery to contract manufacturing, tiered by what stage the business is actually at.
Company has initiated early-stage R&D investments in TIDES (peptides and oligonucleotides), positioning for biotech/biologic-adjacent modalities in the long term, with no current revenue from this area.
“As part of our long-term technology roadmap, we initiated investments in TIDES, covering peptides and oligonucleotides. While these capabilities are still in an early stage of development, they represent a natural extension of our scientific expertise.”
Company describes an aspirational plan to build a CRDMO serving Biopharma (along with Pharma, medical devices, etc.) as part of an ongoing business transition; no specific biotech CRO/CDMO revenue or committed capex/JV is stated.
“In order to align our business with best global opportunities, we are working on a comprehensive plan to build a world class Contract Research, Development and Manufacturing Organization (CRDMO), which will eventually offer end-to-end research, development, manufacturing and allied services to our customers in Pharma, Biopharma, Agro-Chemicals, Medical Devices, Speciality Chemicals and similar industries”
The explanatory statement to the RPT resolution claims the company is renowned for vaccines (which fall under biotech per the theme definition), though the directors' report only describes manufacturing of oral contraceptive tablets and iron tablets as actual operations.
“our Company primarily operates in the generic drugs industry and is renowned for its cost-effective vaccines and medications.”
Objects clause lists pharma/biotech-adjacent activities (vaccines, diagnostic agents, bulk drug intermediates, APIs) among businesses the company is permitted to undertake.
“pharmaceuticals in all its branches, tonics, vitamins, Bulk drugs, vaccines, medical gases, diagnostic agents, surgical & non-surgical articles, A.P.I, Drugs Intermediates, medical, Pharmaceutical Chemicals”
Biopharma is mentioned only as an expanding investment avenue in outlook language, not as a GCM business line.
“Investment avenues in renewable energy, Artificial Intelligence (AI), the electric vehicle (EV) ecosystem, and biopharma are expanding as India aligns with global supply-chain realignments.”
Biotechnology is presented as a vertical of the company's platform, but p3 indicates the actual biotech operations sit in sister group companies (Lords Mark Biotech, Lords Mark Microbiotech) rather than the listed entity directly.
“Cutting-edge biotech solutions, molecular research, diagnostic innovations, and advanced life science solutions engineered for future-ready healthcare.”
Definition used: Discovers, develops or manufactures biologic drugs, vaccines, biosimilars, cell/gene therapies, or provides biotech CRO/CDMO services. Membership is extracted from each company’s newest annual report; every quote is validated against the report page before publishing, and core/growing tiers are confirmed by a second independent read (marked ). Companies whose reports our corpus hasn’t read yet simply aren’t listed — absence means unread, not “no exposure”.
MarketPing publishes facts, filings and measured history only — nothing on this page is investment advice, a recommendation or a rating.
